Boston Scientific's Upcoming Investor Event at the ACC's 75th Annual Scientific Session

Boston Scientific's Upcoming Investor Event

Boston Scientific Corporation is set to hold an important investor event coinciding with the 75th Annual Scientific Session of the American College of Cardiology (ACC) on Saturday, March 28, 2026. The event will commence at 6:30 PM ET (5:30 PM CT) and will include a live webcast, offering participants a chance to engage in crucial discussions surrounding recent clinical data relevant to cardiovascular health.

Dr. Kenneth Stein, who serves as the senior vice president and global chief medical officer, along with Dr. Brad Sutton and Dr. Michael R. Jaff, two other prominent figures in the field, will lead the discussions. Dr. Sutton is recognized as the chief medical officer for AF solutions, while Dr. Jaff brings expertise as the vice president and chief medical officer for vascular therapies. Their insights are expected to illuminate the implications of new clinical findings, underscoring Boston Scientific's commitment to advanced medical solutions that improve patient outcomes.

The investor event is significant as it aligns with Boston Scientific's mission to transform lives through innovative medical technologies. With over 45 years of experience in the medical technology sector, the company continues to address unmet patient needs by offering a diverse range of high-performance solutions. These innovations not only enhance diagnosis and treatment protocols across various medical domains but also aim to decrease healthcare costs effectively.

Accessing the Live Webcast

For interested parties unable to attend the event in person, the live webcast will provide accessibility via the investor relations page on Boston Scientific's website: investors.bostonscientific.com. Participants can expect to find a replay of the session available approximately one hour after its completion, allowing for broader engagement with the content presented.

Boston Scientific's robust portfolio includes devices and therapies that cater to diverse medical fields, including cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions. The company's continuous drive for innovation persists in redefining healthcare standards globally, propelling advancements in treatment methodologies.

As the healthcare industry evolves, events such as the one hosted by Boston Scientific become platforms not only for information dissemination but also for fostering investor confidence and community engagement. Stakeholders, healthcare professionals, and interested parties are encouraged to partake in this unique opportunity to gain insights from leading experts in the field.

This gathering at the ACC's 75th Annual Scientific Session thus represents a momentous occasion that highlights the intersection of innovative medical technology and investor engagement, reaffirming Boston Scientific's role as a pivotal entity in the healthcare landscape.

About Boston Scientific

For further insight into Boston Scientific and its array of products, as well as updates about its initiatives, stakeholders are encouraged to visit their official website at www.bostonscientific.com and follow the company on LinkedIn for the latest news and updates.

Boston Scientific stands at the forefront of improving patient health through cutting-edge technologies and remains dedicated to meeting the needs of healthcare providers and patients alike.